| 注册
首页|期刊导航|中国人兽共患病学报|两种硝基咪唑类抗结核新药对耐多药结核分枝杆菌的药物敏感性分析

两种硝基咪唑类抗结核新药对耐多药结核分枝杆菌的药物敏感性分析

刘文果 朱大冕 冯鑫 沈静 孔珏颖 伏宣霖 胡彦

中国人兽共患病学报2024,Vol.40Issue(3):247-252,256,7.
中国人兽共患病学报2024,Vol.40Issue(3):247-252,256,7.DOI:10.3969/j.issn.1002-2694.2024.00.045

两种硝基咪唑类抗结核新药对耐多药结核分枝杆菌的药物敏感性分析

Drug susceptibility analysis of the nitroimidazoles delamanid and pretomanid against multidrug-resistant Mycobacterium tuberculosis

刘文果 1朱大冕 1冯鑫 1沈静 1孔珏颖 1伏宣霖 1胡彦1

作者信息

  • 1. 重庆市结核病防治所,重庆 400050
  • 折叠

摘要

Abstract

This study analysed and compared the drug susceptibility of two nitroimidazoles drugs delamanid(DLM)and pretomanid(PMD)against multidrug-resistant tuberculosis(MDR-TB)isolates in vitro,so as to provide more datas for the clinical application.Culture positive isolates from 39 county TB dispensary were collected and sent to Chongqing Institute for Tuberculosis Control from November 2021 to February 2023.A total of 198 MDR-TB isolates based on simple random sam-pling were confirmed by strain identification and proportional susceptibility test,and the minimum inhibitory concentrations(MICs)of DLM and PMD were performed by broth microdilution testing.Among the 198 MDR isolates,the baseline resist-ance rates of DLM and PMD were 5.1%(10/198)and 3.5%(7/198)respectively.The MICs range of DLM and PMD against the 198 MDR-TB strains were mainly concentrated in 0.06~1 μg/mL and 0.03~2 μg/mL,respectively.Among the 13 nitroi-midazole resistant isolates,10 isolates were resistant to DLM,7 resistant to PMD,and 4(30.8%,4/13)showed cross-resist-ance between DLM and PMD.In conclusion,DLM and PMD showed excellent antibacterial activities against MDR-TB clinical isolates in vitro.DLM has lower MICs than that of PMD.However,the occurrence of baseline resistance in both new drugs suggested that drug susceptibility testing should be performed prior treatment.

关键词

结核分枝杆菌/德拉马尼/普瑞玛尼/药物敏感性/耐多药

Key words

Mycobacterium tuberculosis/delamanid/pretomanid/drug susceptibility/MDR

分类

医药卫生

引用本文复制引用

刘文果,朱大冕,冯鑫,沈静,孔珏颖,伏宣霖,胡彦..两种硝基咪唑类抗结核新药对耐多药结核分枝杆菌的药物敏感性分析[J].中国人兽共患病学报,2024,40(3):247-252,256,7.

基金项目

重庆市科卫联合医学科研项目(No.2022MSXM102,No.2022-MSXM066) (No.2022MSXM102,No.2022-MSXM066)

重庆市首批公共卫生重点学科(专科)([2022]72) Supported by Chongqing Medical Scientific Research Project(No.2022MSXM102,No.2022MSXM066)and the First Batch of Key Disciplines On Public Health in Chongqing([2022]72) (专科)

中国人兽共患病学报

OA北大核心CSCDCSTPCD

1002-2694

访问量5
|
下载量0
段落导航相关论文